Evidence map›Paper›PMID 42124573›Full record

ArticlebioRxiv : the preprint server for biology2026

Biodegradable Intra-arterial Devices for Focal Drug Delivery to Targeted Organs.

Manas Kinra, Ruoyu Sheng, Yiqing Chen, Amancio Jose de Souza, Anil Bhatia, Garrett Sakomizu, Jinrui Tan, Dongwei Sun, Edward Zagha, Huinan Liu

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Manas KinraDepartment of Molecular, Cell and Systems Biology, University of California at Riverside, Riverside, CA 92521, USA.
Ruoyu ShengDepartment of Bioengineering, University of California at Riverside, Riverside, CA 92521, USA.
Yiqing ChenDepartment of Molecular, Cell and Systems Biology, University of California at Riverside, Riverside, CA 92521, USA.
Amancio Jose de SouzaMetabolomics Core Facility, Institute for Integrative Genome Biology, University of California at Riverside, Riverside, CA 92521, USA.
Anil BhatiaMetabolomics Core Facility, Institute for Integrative Genome Biology, University of California at Riverside, Riverside, CA 92521, USA.
Garrett SakomizuDepartment of Microbiology and Plant Pathology, University of California at Riverside, Riverside, CA 92521, USA.
Jinrui TanDepartment of Bioengineering, University of California at Riverside, Riverside, CA 92521, USA.
Dongwei SunDepartment of Bioengineering, University of California at Riverside, Riverside, CA 92521, USA.
Edward ZaghaDepartment of Molecular, Cell and Systems Biology, University of California at Riverside, Riverside, CA 92521, USA.
Huinan LiuDepartment of Bioengineering, University of California at Riverside, Riverside, CA 92521, USA.

Funding

Controlled focal drug delivery by endovascular bioresorbable composite implantsR03EB035750 · NIBIB · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI LIU, HUINAN HANNAH, ZAGHA, EDWARD W · 2024 to 2025
$158k
NIBIB NIH HHS R03 EB035750
6 · The paper itself

Abstract

This study presents the development of biodegradable intra-arterial drug delivery (IADD) devices for focal treatment of targeted organs, to enhance therapeutic efficacy while minimizing systemic toxicity. The IADD devices are fabricated using magnesium (Mg) and poly(glycerol sebacate) (PGS), leveraging their biocompatibility and tunable biodegradability, and are loaded with two model drugs, i.e., dexamethasone (DEX) or cisplatin (CIS). The IADD devices with helical and linear designs were fabricated for focal drug delivery to targeted organs and characterized for their microstructure and composition using scanning electron microscopy (SEM), energy-dispersive X-ray spectroscopy (EDS), thermogravimetric analysis (TGA), and Fourier-transform infrared spectroscopy (FTIR). The results confirmed the successful incorporation and stability of the drugs within the device. The IADD devices demonstrated a sustained release of DEX and CIS over 30 days

Indexed as

Biocompatible endovascular implantsBiodegradable Intra-arterial drug delivery (IADD) devicesFocal drug deliveryMagnesium based implantsPoly(glycerol sebacate) (PGS)Sustained drug release

Identifiers

PMID42124573
PMCPMC13160102

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.